Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed medicines -- the only ones in the world -- that target the underlying causes of a rare disease called cystic fibrosis (CF).
So far, Vertex's monopoly has remained intact despite many of its peers trying to break into this space. But could that change soon? Sionna Therapeutics, a privately held biotech, certainly hopes so.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
462,50 €
-2,41 %
Die Vertex Pharmaceuticals Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Ein Kursziel von 475 € für Vertex Pharmaceuticals Inc. signalisiert ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 462.5 €.
